Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

By T. Walsh, P. Pappas, D. Winston, H. Lazarus, F. Petersen, J. Raffalli, S. Yanovich, P. Stiff, R. Greenberg, G. Donowitz and 13 more. New England Journal of Medicine, 2002

951 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/8180383ff2669605102320a074953366d5bd8c6e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Perfect
2. D. Kontoyiannis
3. T. Walsh
4. Thierry Calandra
5. E. Anaissie
6. M. Pfaller
7. D. Diekema

In Infectious Diseases

1. D. Kontoyiannis
2. J. Perfect
3. Henry F. Chambers
4. J. Fishman
5. J. Bartlett
6. E. Anaissie
7. M. Pfaller
8. D. Diekema

In Oncology

1. J. Fishman

Citations in the corpus

• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “didiasis for whom additional mold coverage is desired [211].”
• Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, result): “…of voriconazole versus L-AMB did not fulfill prespecified criteria for the overall population but was comparable to L-AMB in the high-risk neutropenic population, with a significant reduction in the rate of emergent invasive aspergillosis during neutropenia in prespecified secondaryanal-yses [262].”
• Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. (2006, background): “Studies examining the efficacy of caspofungin, liposomal amphotericin B, and voriconazole (an azole) have shown very low success rates of ∼40% [41–43].”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, background): “for whom additional mold coverage is desired [92].”
• Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. (2005, neutral): “VRC as prophylaxis and as empirical [5], preemptive,”
• Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. (2008, background): “However, no data on voriconazole levels were reported [2, 22].”
• Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (2008, background): “efficacy, in strategy trials [2–6], for the formulation of clinical”
• Practice guidelines for the diagnosis and management of skin and soft-tissue infections. (2005, background): “Recently, 2 randomized, international, multicenter trials found that caspofungin [181] and voriconazole [182] were each suitable alternatives to amphotericin B in this patient population.”
• Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “liposomal AmB in the high-risk neutropenic population, with a significant reduction in the rate of emergent IA [583].”
• Guidelines for treatment of candidiasis. (2004, background): “, allogeneic bone marrow transplant recipients and individuals with relapsed leukemia) for prevention of breakthrough fungal infections [147].”
• Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). (2007, background): “More than 1300 patients received liposomal amphotericin B at 3 mg/kg per day in 3 major clinical trials of empirical antifungal therapy for febrile neutropenia [7, 22, 23].”